Sumitomo Chemical Co., Ltd. · TSE:4005

Sumitomo Chemical — Q2 2027 Earnings Presentation

32 slides from Sumitomo Chemical's earnings presentation, Nov 2, 2026

  1. Slide 1: Financial Results for FY2026 Second Quarter

    Financial Results for FY2026 Second Quarter (April 1, 2026 – September 30, 2026) November 2, 2026

  2. Slide 2: Cautionary Statement

    (Cautionary Statement) Statements made in this material with respect to Sumitomo Chemical’s current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management’s assu

  3. Slide 3: Contents

    Contents 2 1. Consolidated Financial Results for (Reference) FY2026 Second Quarter Sales Revenue Summary for FY2026 First Half ・・・・・・・・・・・・・・・・ 4 by Reporting Segment (Quarterly) ・・・・・・・・・・・・・・・・・ 21 Consolidated Financial Results Summary・・・・・・・・ 5 Core Operating Income Sales Revenue by Reporting Se

  4. Slide 4: 1. Consolidated Financial Results for FY2026 Second Quarter

    1. Consolidated Financial Results for FY2026 Second Quarter

  5. Slide 5: Summary for FY2026 First Half

    Summary for FY2026 First Half 4 Core Operating Income Net Income Attributable to Owners of the Parent (Billions of yen) (Billions of yen) FY2026 FY2026 Q2 FY2025 Q2 FY2026 Forecast Q2 FY2025 Q2 FY2026 Forecast (announced in Aug.) (announced in Aug.) 108.7 144.5 125.0 39.7 82.9 70.0 ※Excluding gains

  6. Slide 6: Consolidated Financial Results Summary

    Consolidated Financial Results Summary 5 (Billions of yen) Variance Q2 FY2026 Q2 FY2025 Variance Ratio Sales revenue 1,172.8 1,095.4 77.4 7.1% Core operating income 144.5 108.7 35.8 32.9% of which equity-method investments 36.7 (27.3) 64.0 - Total non-recurring items (breakdown below) (6.5) (5.0) (1

  7. Slide 7: Sales Revenue by Reporting Segment

    Sales Revenue by Reporting Segment 6 (Billions of yen) Sales Shipping Foreign currency Q2 FY2026 Q2 FY2025 Variance Variance Ratio price volume (FX) conversion variance variance variance Agro & Life Solutions 226.5 213.0 13.5 6.4% 15.0 (15.3) 13.8 ICT & Mobility Solutions 311.9 283.5 28.4 10.0% 7.0

  8. Slide 8: Core Operating Income by Reporting Segment

    Core Operating Income by Reporting Segment 7 (Billions of yen) Shipping volume Price Cost Q2 FY2026 Q2 FY2025 Variance variance variance variance and other Agro & Life Solutions 20.8 11.2 9.6 11.0 0.0 (1.4) ICT & Mobility Solutions 31.9 33.1 (1.2) (4.5) (3.0) 6.3 Advanced Medical Solutions (3.7) (1.

  9. Slide 9: Core Operating Income Analysis: Agro & Life Solutions

    Core Operating Income Analysis by Reporting Segment 8 Agro & Life Solutions Total ¥ 20.8 billion ¥ 9.6 billion from Q2 FY2025 11.0 0.0 (1.4) Feed Additives(-) 20.8 11.2 Feed Additives(+) Crop Protection(-) Q2 FY2025 Price Cost Volume Q2 FY2026 and other Crop Protection Slow recovery in business envi

  10. Slide 10: Core Operating Income Analysis: ICT & Mobility Solutions

    Core Operating Income Analysis by Reporting Segment 9 ICT & Mobility Solutions Total ¥ 31.9 billion ¥ (1.2) billion from Q2 FY2025 6.3 (4.5) (3.0) 33.1 Displays(-) Semiconductors(+) 31.9 Mobility(+) Semiconductors(-) Displays(-) Q2 FY2025 Price Cost Volume Q2 FY2026 and other Absence of prior year g

  11. Slide 11: Core Operating Income Analysis: Advanced Medical Solutions

    Core Operating Income Analysis by Reporting Segment 10 Advanced Medical Solutions Total ¥ (3.7) billion ¥ (2.3) billion from Q2 FY2025 (1.4) 0.0 (3.7) (1.0) (1.3) Q2 FY2025 Price Cost Volume Q2 FY2026 and other Difference in sales mix of active pharmaceutical ingredients and intermediates (Volume an

  12. Slide 12: Core Operating Income Analysis: Essential & Green Materials

    Core Operating Income Analysis by Reporting Segment 11 Essential & Green Materials Total ¥ 62.1 billion ¥ 80.7 billion from Q2 FY2025 63.7 Japan(+) Singapore(+) Saudi Arabia(+) 62.1 13.5 3.5 (18.6) Q2 FY2025 Price Cost Volume Q2 FY2026 and other Japan Inventory valuation gains (Price(+)) Singapore I

  13. Slide 13: Core Operating Income Analysis: Sumitomo Pharma

    Core Operating Income Analysis by Reporting Segment 12 Sumitomo Pharma Total ¥ 43.6 billion ¥ (53.8) billion from Q2 FY2025 (1.5) (5.0) 97.3 (47.3) 43.6 Q2 FY2025 Price Cost Volume Q2 FY2026 and other Partial sale of the Asian business in the prior year (Volume and other(-), Cost(+)) Increase in sel

  14. Slide 14: Consolidated Statement of Financial Position

    Consolidated Statement of Financial Position 13 (Billions of yen) 30-Sep-26 31-Mar-26 Variance 30-Sep-26 31-Mar-26 Variance Current assets 1,623.0 1,507.7 115.3 Liabilities 2,143.5 2,168.4 (24.9) Cash and cash equivalents 208.4 208.6 (0.2) Trade and other payables 529.8 464.4 65.4 Trade and other re

  15. Slide 15: Consolidated Statement of Cash Flows

    Consolidated Statement of Cash Flows 14 (Billions of yen) Q2 FY2026 Q2 FY2025 Variance Cash flows from operating activities 66.6 57.7 8.9 Cash flows from investing activities (84.9) (16.7) (68.2) Free cash flows (18.3) 41.0 (59.3) Cash flows from financing activities 16.0 (114.8) 130.8 Others 2.2 2.

  16. Slide 16: 2. Outlook for FY2026

    2. Outlook for FY2026 & SUMITOMO CHEMICAL

  17. Slide 17: Outlook for the Business Environment

    Outlook for the Business Environment 16 Economic Conditions  Although growth in the field of technology is firmly supporting the global economy, future prospects remain uncertain due to geopolitical risks, including tensions in the Middle East. Business Environment There has been a delay in recover

  18. Slide 18: Summary of the Financial Forecast for FY2026

    Summary of the Financial Forecast for FY2026 17 Forecast for FY2026 Trend in core operating income Core operating income: projected to be 270.0 billion yen, an upward (Billions of yen) revision from 215.0 billion yen 300.0 Net income attributable to owners of the parent: projected to reach 90.0 270.

  19. Slide 19: Performance Forecast for FY2026

    Performance Forecast for FY2026 18 (Billions of yen) Previous Revised Variance FY2025 forecast Variance forecast ratio actual (announced in May) Sales revenue 2,490.0 2,360.0 130.0 5.5% 2,328.5 Core operating income 270.0 215.0 55.0 25.6% 208.4 Non-recurring items (55.0) (38.0) (17.0) - (56.6) Opera

  20. Slide 20: Sales Revenue and Core Operating Income by Reporting Segment

    Sales Revenue and Core Operating Income by Reporting Segment 19 (Billions of yen) Previous Revised FY2025 forecast Variance forecast actual (announced in May) Agro & Life Solutions Sales Revenue 570.0 560.0 10.0 519.3 Core Operating Income 65.0 65.0 - 56.3 ICT & Mobility Solutions Sales Revenue 610.

  21. Slide 21: (Reference)

    (Reference) & SUMITOMO CHEMICAL

  22. Slide 22: Sales Revenue by Reporting Segment (Quarterly)

    Sales Revenue by Reporting Segment (Quarterly) 21 (Billions of yen) FY2025 FY2026 2nd Half Q1 Q2 Q3 Q4 Q1 Q2 1st Half (Forecast) Agro & Life Solutions 96.9 116.1 133.9 172.4 109.0 117.5 226.5 343.5 ICT & Mobility Solutions 137.4 146.1 148.3 142.4 148.6 163.3 311.9 298.1 Advanced Medical Solutions 9.

  23. Slide 23: Core Operating Income by Reporting Segment (Quarterly)

    Core Operating Income by Reporting Segment (Quarterly) 22 (Billions of yen) FY2025 FY2026 2nd Half Q1 Q2 Q3 Q4 Q1 Q2 1st Half (Forecast) Agro & Life Solutions 2.2 9.0 16.9 28.2 9.6 11.2 20.8 44.2 ICT & Mobility Solutions 18.4 14.7 13.4 6.5 13.0 18.9 31.9 28.1 Advanced Medical Solutions (1.0) (0.4) 1

  24. Slide 24: Sales Revenue Analysis: Agro & Life Solutions

    Sales Revenue Analysis by Reporting Segment 23 Agro & Life Solutions Total ¥ 226.5 billion ¥ 13.5 billion from Q2 FY2025 15.0 13.8 (15.3) Feed Additives(+) 213.0 Crop protection(-) Crop protection(-) Crop protection(+) 226.5 Feed Additives(-) Q2 FY2025 Price Volume FX Q2 FY2026 Weaker yen’s effect o

  25. Slide 25: Sales Revenue Analysis: ICT & Mobility Solutions

    Sales Revenue Analysis by Reporting Segment 24 ICT & Mobility Solutions Total ¥ 311.9 billion ¥ 28.4 billion from Q2 FY2025 17.1 7.0 4.4 311.9 Semiconductors(+) Semiconductors(+) Displays(-) 283.5 Mobility(+) Displays(-) Q2 FY2025 Price Volume FX Q2 FY2026 Decline in mobile related shipments due to

  26. Slide 26: Sales Revenue Analysis: Advanced Medical Solutions

    Sales Revenue Analysis by Reporting Segment 25 Advanced Medical Solutions Total ¥ 21.5 billion ¥ 0.3 billion from Q2 FY2025 0.0 0.3 0.1 21.1 21.5 Q2 FY2025 Price Volume FX Q2 FY2026 Difference in shipments timing for active pharmaceutical ingredients and intermediates (Volume(+))

  27. Slide 27: Sales Revenue Analysis: Essential & Green Materials

    Sales Revenue Analysis by Reporting Segment 26 Essential & Green Materials Total ¥ 320.9 billion ¥ (8.3) billion from Q2 FY2025 63.5 9.4 (81.2) Japan(+) 329.1 Singapore(+) Japan(-) 320.9 Singapore(-) Q2 FY2025 Price Volume FX Q2 FY2026 Japan Increase in raw material and product market prices (Price(

  28. Slide 28: Sales Revenue Analysis: Sumitomo Pharma

    Sales Revenue Analysis by Reporting Segment 27 Sumitomo Pharma Total ¥ 265.5 billion ¥ 39.4 billion from Q2 FY2025 23.2 17.8 (1.5) 226.1 265.5 Q2 FY2025 Price Volume FX Q2 FY2026 Increase in sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and GEMTESA® (treatment for overactive bla

  29. Slide 29: Cost and other Elements

    Cost and other Elements 28 (Billions of yen) Q2 FY2026 Q2 FY2025 Variance Capital Expenditures 52.1 58.0 (5.9) Depreciation and Amortization 59.1 60.0 (0.8) Research & Development Expenses 74.3 67.0 7.3 Number of Employees (as of September 30) 26,972 27,699 (727)

  30. Slide 30: Cost and other Elements by Reporting Segment

    Cost and other Elements by Reporting Segment 29 (Billions of yen) Depreciation& Capital Expenditures R&D Expenses Amortization Q2 FY2026 Q2 FY2025 Q2 FY2026 Q2 FY2025 Q2 FY2026 Q2 FY2025 Agro & Life Solutions 7.8 7.1 10.9 10.1 16.9 14.9 ICT & Mobility Solutions 20.8 26.3 18.2 16.3 18.2 16.3 Advanced

  31. Slide 31: Major Group Companies

    Major Group Companies 30 Sales Revenue Company Profit Q2 FY2026 Q2 FY2025 The Polyolefin Company (Singapore) 377 390 Inventory valuation gains (Millions of USD) PCS 929 1,115 Inventory valuation gains (Millions of USD) Rabigh Refining and Impact of prior year shutdown maintenance and Petrochemical C

  32. Slide 32: Crop Protection Product Sales by Region

    Crop Protection Product Sales by Region 31 (Billions of yen) Q2 FY2026 Q2 FY2025 Variance Reasons for Change Japan 32.7 34.0 (1.3) • Decrease in shipments due to North America 18.1 21.2 (3.1) delayed sales • Increase in revenue due to foreign currency conversion variance, etc., Central & South Ameri

Sumitomo Chemical Company — Q2 2027 Earnings Presentation on 6ix